Business
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The layoffs are in departments across the company that aren’t central to its consumer testing and therapeutics business.
Kapoor was found guilty in May 2019 of orchestrating kickback schemes to encourage doctors to boost prescriptions of Subsys, a powerful pain killer.
Pharma and life sciences companies strengthen their leadership and boards with this week’s appointments.
The new entity, funded by $55 million from the BCBS businesses, was born as a response to the high costs of prescription medicines in the United States and concerns about the overall affordability of health care.
Coherus BioSciences, Inc. announced the Company has entered into a licensing agreement with Innovent Biologics, Co., Ltd.,, a leading biopharmaceutical company headquartered in China, to commercialize Innovent’s biosimilar candidate to Avastin® in the United States and Canada.
Armon Sharei, chief executive officer of SQZ Biotech, said 2020 is going to be an exciting year for the company as it anticipates having clinical data available from its first trial by the end of this year.
Amphora is a viscous and bioadhesive contraceptive, packaged in a prefilled applicator.
Sensyne Health plc, the British Clinical AI technology company, announces its Interim Results for the 6 months ended 31 October 2019.
Albert Baehny, chairman of the board of directors, said the company looks forward to the coming challenges of 2020, including the naming of a new CEO.
PhoreMost and Otsuka Pharmaceutical Co. entered into a multi-project collaboration to seek out disease-relevant pathways that can be exploited for the development of gene therapies to treat different illnesses.